FI90990C - Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi - Google Patents

Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi

Info

Publication number
FI90990C
FI90990C FI854994A FI854994A FI90990C FI 90990 C FI90990 C FI 90990C FI 854994 A FI854994 A FI 854994A FI 854994 A FI854994 A FI 854994A FI 90990 C FI90990 C FI 90990C
Authority
FI
Finland
Prior art keywords
recombinant dna
dna molecule
host organism
transformed host
producing interferon
Prior art date
Application number
FI854994A
Other languages
English (en)
Swedish (sv)
Other versions
FI854994A0 (fi
FI854994L (fi
FI90990B (fi
Inventor
Adolf Himmler
Rudolf Hauptmann
Norbert Hauel
Guenther Adolf
Peter Swetly
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of FI854994A0 publication Critical patent/FI854994A0/fi
Publication of FI854994L publication Critical patent/FI854994L/fi
Application granted granted Critical
Publication of FI90990B publication Critical patent/FI90990B/fi
Publication of FI90990C publication Critical patent/FI90990C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
FI854994A 1984-12-18 1985-12-16 Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi FI90990C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3446124 1984-12-18
DE3446122 1984-12-18
DE3529262 1985-08-16
DE3535115 1985-10-02

Publications (4)

Publication Number Publication Date
FI854994A0 FI854994A0 (fi) 1985-12-16
FI854994L FI854994L (fi) 1986-06-19
FI90990B FI90990B (fi) 1994-01-14
FI90990C true FI90990C (fi) 1994-04-25

Family

ID=27433247

Family Applications (1)

Application Number Title Priority Date Filing Date
FI854994A FI90990C (fi) 1984-12-18 1985-12-16 Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi

Country Status (19)

Country Link
US (2) US5605688A (fi)
EP (1) EP0186098B1 (fi)
JP (1) JPH0753596A (fi)
KR (1) KR940010864B1 (fi)
AT (1) ATE77410T1 (fi)
AU (1) AU604634B2 (fi)
CA (1) CA1339954C (fi)
DE (1) DE3544520C2 (fi)
DK (1) DK167929B1 (fi)
ES (1) ES8704515A1 (fi)
FI (1) FI90990C (fi)
GR (1) GR853062B (fi)
HU (1) HU212836B (fi)
IE (1) IE58685B1 (fi)
IL (1) IL77369A (fi)
NO (1) NO176057C (fi)
NZ (1) NZ214602A (fi)
PT (1) PT81691B (fi)
WO (1) WO1986003775A1 (fi)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90990C (fi) * 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
DE3642096A1 (de) * 1986-12-10 1988-06-16 Boehringer Ingelheim Int Pferde-(gamma)-interferon
DE3932311A1 (de) * 1989-09-28 1991-04-11 Boehringer Ingelheim Int Verfahren zur reinigung von beta-interferon
USRE40374E1 (en) 1998-05-29 2008-06-10 Heska Corporation Canine IL-13 immunoregulatory proteins and uses thereof
US6482403B1 (en) 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
CA2329052A1 (en) 1998-05-29 1999-12-02 Heska Corporation Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
US20020127200A1 (en) 1998-05-29 2002-09-12 Shumin Yang Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
BR0115392A (pt) 2000-11-03 2004-06-15 Biomedicines Inc Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
US20030143197A1 (en) * 2001-11-09 2003-07-31 Moran S. Mark Method for treating diseases with omega interferon
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
SMT201800221T1 (it) 2011-03-15 2018-07-17 Biogen Ma Inc Metodo per ridurre i sintomi simil-influenzali associati alla somministrazione intramuscolare di interferone utilizzando un regime di dosaggio crescente a titolazione rapida
CN102321169A (zh) * 2011-09-30 2012-01-18 长春工业大学 一种犬重组干扰素α及制备方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
CN108486127A (zh) * 2018-01-12 2018-09-04 中国农业科学院北京畜牧兽医研究所 犬干扰素-α6α7重组蛋白及其制备方法与应用
CN108424915A (zh) * 2018-01-12 2018-08-21 中国农业科学院北京畜牧兽医研究所 犬干扰素-α2重组蛋白的制备方法
CN111233997B (zh) * 2018-08-02 2022-04-12 中国农业科学院北京畜牧兽医研究所 一种重组犬干扰素CaIFN-λ突变体及其应用
GB202011945D0 (en) * 2020-07-31 2020-09-16 Ilc Therapeutics Ltd Compositions and methods relating to the treatment of diseases
CN112079912B (zh) * 2020-09-25 2022-05-06 广州源博医药科技有限公司 一种高活性的犬α干扰素重组蛋白及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980002375A1 (en) * 1977-09-23 1980-11-13 Hem Res Inc High purity animal interferons
US4262090A (en) * 1979-06-04 1981-04-14 Cetus Corporation Interferon production
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
EP0042246B1 (en) * 1980-06-12 1987-03-18 The Cancer Institute Of Japanese Foundation For Cancer Research Plasmid
US4436815A (en) * 1981-11-27 1984-03-13 Eli Lilly And Company Method for stabilizing and selecting recombinant DNA containing host cells
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
IL68561A (en) * 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
JPS60118196A (ja) * 1983-11-30 1985-06-25 Takeda Chem Ind Ltd インタ−フェロンの製造法
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
FI90990C (fi) * 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
US4689224A (en) * 1985-10-07 1987-08-25 Neogen Corporation Method for administering vaccines containing equine leukokines and compositions therefor

Also Published As

Publication number Publication date
ES8704515A1 (es) 1987-04-01
GR853062B (fi) 1986-04-21
ES550043A0 (es) 1987-04-01
EP0186098A1 (de) 1986-07-02
IE853194L (en) 1986-06-18
US5798228A (en) 1998-08-25
WO1986003775A1 (fr) 1986-07-03
AU604634B2 (en) 1991-01-03
IE58685B1 (en) 1994-02-09
KR940010864B1 (ko) 1994-11-18
JPH0753596A (ja) 1995-02-28
PT81691B (pt) 1988-04-21
US5605688A (en) 1997-02-25
HU212836B (en) 1996-12-30
EP0186098B1 (de) 1992-06-17
DE3544520A1 (de) 1986-12-18
DK167929B1 (da) 1994-01-03
FI854994A0 (fi) 1985-12-16
NO176057B (no) 1994-10-17
DK586585D0 (da) 1985-12-17
AU5132085A (en) 1986-06-26
NO855078L (no) 1986-06-19
IL77369A (en) 1993-07-08
DK586585A (da) 1986-06-19
NO176057C (no) 1995-01-25
DE3544520C2 (de) 1995-07-20
HUT40165A (en) 1986-11-28
PT81691A (de) 1986-01-01
CA1339954C (en) 1998-07-14
FI854994L (fi) 1986-06-19
ATE77410T1 (de) 1992-07-15
NZ214602A (en) 1991-06-25
FI90990B (fi) 1994-01-14
KR860005020A (ko) 1986-07-16

Similar Documents

Publication Publication Date Title
FI90990C (fi) Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
FI831818L (fi) Mikrobiologiskt framstaellda - och -interferoner, dessa interferoner kodande dna-sekvenser, dennagenetiska information innehaollande mikroorganismer och deras framstaellningsfoerfarande
FI98217B (fi) Menetelmä nekroositekijän valmistamiseksi
FI99015B (fi) Menetelmä biologisesti aktiivisen kasvaimen nekroositekijä-proteiinin muteiinin valmistamiseksi
FI99116B (fi) Menetelmä valmistaa hevosen -interferonia
FI90667C (fi) Menetelmä valmistaa uutta ihmisen tyypin I interferoniproteiinia
EP0676413A3 (en) Interferon alpha / beta binding protein, its production and application.
SE8502430D0 (sv) A cdna molecule coding for the expression of an interferon alfa type polypeptide, a bacterial or cellular host transformed with such molecule and a polypeptide showing interferon activity prepared by such host
DE59106112D1 (de) Verfahren zur Inaktivierung der biologischen Aktivität von DNA.
PT101697A (pt) Processo para a preparacao de um factor de regulacao de expressao genetica
KR870011246A (ko) 인간 β-인터페론 유전자를 지닌 대장균 유전자 운반체의 제조방법

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH